Jiandong Wen1, Qiao Shu2, Yueqiong Li3, *


1Department of Pharmacy, Ganzhou People's Hospital, Ganzhou 341000, Jiangxi Province, China - 2Department of Nephrology, Ganzhou People's Hospital, Ganzhou 341000, Jiangxi Province, China - 3Department of Foreign Cooperation Office, Ganzhou People's Hospital, Ganzhou 341000, Jiangxi Province, China


This study aimed to explore the efficacy of thymopentin and BoZhi glycopeptide in the treatment of patients with maintenance hemodialysis (MHD) and the effects on immune function and concurrent infection of patients. Seventy-eight patients with chronic kidney disease who received treatment from February 2021 to June 2022 were included as the study subjects. They were randomly divided into 3 groups, with 26 patients in each group. All patients were treated with hemodialysis and medication for 3 months. Group 1 was treated with placebo (normal saline, 2 mL once a week), group 2 was treated with BoZhi Glycopeptide (2 mL once a week), and group 3 was treated with thymopentin (10 mg once a week). After treatment, the proportions of T-cell subsets (CD4+, CD8+, CD4+/CD8+), interleukin-2 (IL-2), IL-8, and hypersensitive C-reactive protein (hsCRP) were detected. Patients were followed up for one year, and upper respiratory tract infections were counted. The results showed that the levels of CD4+, CD4+/CD8+, and IL-2 in group 2 and group 3 were considerably increased versus group 1 (P<0.05), while IL-8 and hs-CRP levels were considerably decreased (P<0.05). The prevalence of respiratory infection and the degree of medication were remarkable in patients in group 2 and group 3 during the six-month follow-up period (P<0.05). In summary, thymopentin and BoZhi glycopeptide had remarkable efficacy in improving immune function and controlling respiratory tract infections in MHD patients, which is worthy of promotion.


Maintenance hemodialysis, thymus pentapeptide, Bozhi glycopeptide, immune function, respiratory tract infection.